Flow Cytometry Global Market Report 2023 – By Type (Instruments, Reagents & Consumables, Software, Accessories, Services), By Technology (CellBased, BeadBased), By Application (Oncology, Drug Discovery, Disease Diagnosis, Stem Cell Therapy, Organ Transplantation, Hematology),By End User (Hospitals And Clinics, Academia And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

The oxygen flow meter measures and regulates the amount of oxygen delivered to patients who are receiving oxygen therapy. It can not only accurately detect the flow of oxygen in real-time, but it can also keep healthcare providers informed about a patient's oxygen absorption status. Oxygen flowmeters are now routinely utilized in hospitals at all levels. The main types of oxygen flow meters are double flange type, plug-in type, and others. Plug-in type O2 flow meters are mostly used in the healthcare industry, such as in hospitals, surgical facilities, and clinics, to monitor or control high-pressured oxygen provided from an O2 cylinder. The different calibration types include automatic and manual and are used in healthcare, industrial, aerospace, chemical, and other applications. The global oxygen flow meters market is segmented - 1) By Type: Double Flange Type, Plug-in Type, Other Types 2) By Calibration Type: Automatic, Manual 3) By Application: Healthcare, Industrial, Aerospace, Chemical, Other Applications The global oxygen flow meters market size grew from $1.54 billion in 2022 to $1.68 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global oxygen flow meters market size is expected to grow to $2.31 billion in 2027 at a CAGR of 8.2%. The increasing number of COVID-19 cases in the world is expected to propel the growth of the oxygen flowmeter market going forward. COVID-19 disease (COVID-19) is an infectious disease caused by the virus called SARS-CoV-2. The majority of those infected with the virus will experience mild to moderate respiratory symptoms and require external oxygen to breathe. For instance, according to the Worldometer, a US-based reference website that provides live world statistics, the total new COVID-19 cases found on 25th April 2022 is 510 million, has jumped to 511 million on 27th April 2022. Therefore, the increasing number of COVID-19 cases drives the oxygen flowmeter market. Major players in the oxygen flow meters market are D.Z. Medicale S.r.l., Heyer Medical AG, Ohio Medical Corporation, Megasan Medical, Precision Medical Inc., HERSILL, Penlon Ltd., BURAK Metering Pvt. Ltd., Amcaremed Technology Co. Limited, Dwyer Instruments Ltd., Burak Metering, Deluxe Industrial Gases, Sumukha Meditek, and Ashish Engineering. New product developments have emerged as a key trend gaining popularity in the oxygen flowmeters market. Major companies operating in the oxygen flowmeters sector are focused on new product innovations to meet consumer demand and strengthen their position. For instance, In August 2021, Guangzhou Aosong Electronics Company Ltd., a China-based manufacturer of temperature and humidity sensors, launched a new intelligent digital gas mass flow meter based on advanced semiconductor technology. This product features high sensitivity, a versatile output mode, and a wide range of stability. The AMS2106 uses thermal mass flow measurement without the need for additional temperature and pressure correction from the client, ensuring high-precision flowmeter calculations, high sensitivity, and the ability to quickly detect the minimum starting flow rate and begin the calculation. In January 2022, ICU Medical Inc., a US-based medical company, acquired Smiths Medical for an undisclosed amount. With this acquisition, ICU Medical Inc will continue providing innovation, quality, and value to clinical customers worldwide. Smiths Medical is a US-based company that provides oxygen flow meters. North America was the largest region in the oxygen flow meters market in 2022. The regions covered in the oxygen flow meters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oxygen flow meters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The oxygen flow meter market consists of sales of thorpe tube oxygen flow meter, bourdon gauge oxygen flow meter, and dial/click oxygen flow meter. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The oxygen flow meters market research report is one of a series of new reports from The Business Research Company that provides oxygen flow meters market statistics, including oxygen flow meters industry global market size, regional shares, competitors with a oxygen flow meters market share, detailed oxygen flow meters market segments, market trends and opportunities, and any further data you may need to thrive in the oxygen flow meters industry. This oxygen flow meters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug discovery is the process of identifying biologically active compounds that possess the potential to become therapeutic agents. The drug discovery process involves different phases, from ideation to development to approval. It is used to discover a new clinical drug for treating new, existing, and previously incurable diseases. The main types of drugs in the drug discovery market are small molecule and large molecule. The small molecules are used to identify small molecules with suitable properties for development. Small molecule refers to a low molecular weight drug that can smoothly penetrate cells. The various processes in drug discovery includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The various technologies in drug discovery includes high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, nanotechnology, and other technologies. The drug discovery is applied in many therapeutic areas such as oncology, neurology, infectious and immune system diseases, digestive system diseases, cardiovascular diseases, diabetes, respiratory disease, and other therapeutic areas. The drug discovery is used by pharmaceutical companies, CROs, and other end-users. The global drug discovery market is segmented - 1) By Drug Type: Small Molecule, Large Molecule 2) By Process: Target Selection, Target Validation, Hit-to-Lead Identification, Lead Optimization, Candidate Validation 3) By Technology: High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics and Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies 4) By Therapeutic Area: Oncology, Neurology, Infectious and Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Diabetes, Respiratory Disease, Other Therapeutic Areas 5) By End User: Pharmaceutical Companies, CROs, Other End-Users The global drug discovery market size will grow from $85.42 billion in 2022 to $98.48 billion in 2023 at a compound annual growth rate (CAGR) of 15.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the drug discovery is expected to grow to $158.67 billion in 2027 at a CAGR of 12.7%. Rising healthcare expenditure is expected to propel the drug discovery market going forward. Countries around the world are spending a major share of their GDP on healthcare expenses which include hospital care, physician and clinical services, other professional services, dental services, other health, residential, and personal care, home health care, nursing care facilities, and continuing care retirement communities, prescription drugs, and others. Drug discovery holds a significant part of the health expenditure, as it is required to treat diseases and prolong life. There is an increasing need for new drugs to treat new diseases. For instance, In 2020, the US National Healthcare Expenditure (NHE) grew by 9.7% to $4.1 trillion, accounting for 19.7% of the U.S. Gross Domestic Product (GDP). Therefore, rising healthcare expenditure is expected to propel the drug discovery market growth. Major players in the drug discovery market are Pfizer Inc., GlaxoSmithKline PLC, Merck & Co. Inc., Agilent Technologies Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bayer AG, Abbott Laboratories Inc., AstraZeneca PLC, Shimadzu Corp., Evotec SE, Boehringer Ingelheim, Inc., Novartis, Johnson & Johnson, and WIL Research Laboratories. Technological advancements are a key trend in the drug discovery market. Companies operating in the drug discovery market are coming up with various new technologies, such as AI, imaging technology, and others, to reduce the time required for drug discovery. The imaging technology enables non-invasive biological activities occurring within organisms in response to medications to be visualised, characterised, and quantified. These methods, which make use of the strengths of either probes or tissue itself, are crucial for understanding diseases and finding new treatments. For instance, in October 2020, the CU Skaggs School of Pharmacy and Pharmaceutical Sciences, part of Colorado Anschutz, a US-based medical university, announced a new drug discovery technology that includes a new robotic screening and imaging technology which cuts the screening time for new drug therapies by half and also enables rapid and cost-effective screening of hundreds of thousands of potential therapies for diseases. In October 2021, Inotiv, a US-based contract research organization that focuses on nonclinical and analytical drug discovery and development services, acquired Plato BioPharma for $15 million. Through this acquisition, Inotiv intends to execute its strategy of developing a comprehensive range of contract research services spanning the entire drug discovery and preclinical development process. Plato BioPharma is a US-based company specialising in vivo pharmacology research and drug discovery in the cardiovascular, renal, pulmonary, and hepatic therapeutic areas. North America was the largest region in the drug discovery market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The drug discovery market includes revenues earned by entities by high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, and nanotechnology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug discovery market research report is one of a series of new reports from The Business Research Company that provides drug discovery market statistics, including drug discovery industry global market size, regional shares, competitors with a drug discovery market share, detailed drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery industry. This drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell therapy refers to a form of regenerative medicine that uses stem cells or their byproducts to stimulate the body's natural repair process in damaged, malfunctioning, or wounded tissue. It is the next step in the transplantation of organs, replacing donor organs—which are scarce—with cells. The main types of stem cell therapy are allogeneic stem cell therapy and autologous stem cell therapy. Allogeneic stem cell transplantation involves transferring stem cells from a healthy person (the donor) to the patient's body after high-intensity chemotherapy or radiation. The various sources of the cells include adult stem cells, induced pluripotent stem cells, and embryonic stem cells that are used for the treatment of musculoskeletal disorders, wounds and injuries, cancer, autoimmune disorders, and others. The therapies are used by hospitals and clinics. The global stem cell therapy market is segmented – 1) By Type: Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy 2) By Cell Source: Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells 3) By Application: Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, Other Applications 4) By End-User: Hospitals, Clinics The global stem cell therapy market size will grow from $5.14 billion in 2022 to $6.45 billion in 2023 at a compound annual growth rate (CAGR) of 25.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global stem cell therapy market size is expected to grow to $11.88 billion in 2027 at a CAGR of 16.5%. The rising prevalence of chronic diseases contributed to the growth of the stem cell therapy market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases among people, thus driving the need for stem cell therapy. According to a United Nations article, by 2030, the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic diseases is expected to reach about 60%. The rising prevalence of chronic diseases is expected to drive the stem cell therapy market growth. Major players in the stem cell therapy market are Anterogen, JCR Pharmaceuticals, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, Gamida Cell, Capricor Therapeutics, Cellular Dynamics, CESCA Therapeutics, DiscGenics, OxStem, Mesoblast, ReNeuron Group, Takeda Pharmaceuticals, Magellan, Kolon TissueGene, Stemedica Cell Technologies, Holostem Terapie Avanzate S.r.l., NuVasive, RTI Surgical and AlloSource. The high cost of stem cell therapy is expected to limit the growth of the stem cell therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for chronic diseases has impacted the health conditions of the population and has led to a low average life expectancy. According to the DVCSTEM, the average cost of stem cell therapy in the USA is between $20,000 to $25,000, in Mexico, it is $33,000, in Central America, it is $30,000, and in Asia, it is $50,000, thus restraining the stem cell therapy market growth. The companies in the stem cell therapy market are increasingly investing in strategic partnerships. A strategic partnership is a mutually beneficial agreement between two companies that do not compete directly with each other. For instance, in June 2020, Shanghai Cell Therapy Group (SHCell) has recently begun a six-year research collaboration with Professor Qi-Long Ying of the University of Southern California (USC). The Ying laboratory hopes to develop conditions for long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells through the project, which is supported by $3.6 million from the Baize Plan Fund. In July 2020, Boehringer Ingelheim, a Germany-based pharmaceutical company, acquired Global Stem Cell Technology (GST) for an undisclosed amount. The acquisition completely supports Boehringer Ingelheim's Animal Health strategy, which aims to improve its portfolio capabilities to spur innovation and growth. The purchase comes after a two-year, fruitful relationship that saw the introduction of the first-ever registered stem cell-based veterinary treatment to the European market. GST is a Belgian biotech company that develops and produces state-of-the art stem cell products for horses and pets. North America was the largest region in the stem cell therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global stem cell therapy market during the forecast period. The regions covered in the global stem cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the stem cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The stem cell therapy market includes revenues earned by entities by hematopoietic stem cells, skin stem cells, neural stem cells, and mesenchymal stem cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The stem cell therapy market research report is one of a series of new reports from The Business Research Company that provides stem cell therapy market statistics, including stem cell therapy industry global market size, regional shares, competitors with a stem cell therapy market share, detailed stem cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy industry. This stem cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes, and neurons. The main derived cell types of induced pluripotent cells are hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes are the liver's primary functional cells, performing a staggering array of metabolic, endocrine, and secretory tasks. The various application includes academic research, drug development, and discovery, toxicity screening, and regenerative medicine and are used in several sectors such as hospitals, and research laboratories. The global induced pluripotent stem cell (iPSC) market is segmented - 1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cells 2) By Application: Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine 3) By End-User: Hospitals, Research Laboratories The global induced pluripotent stem cell (ipsc) market size will grow from $2.69 billion in 2022 to $2.97 billion in 2023 at a compound annual growth rate (CAGR) of 10.5% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global induced pluripotent stem cell (ipsc) market is expected to grow to $4.36 billion in 2027 at a CAGR of 10.1% . An increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell. Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment market. Major players in the induced pluripotent stem cell (iPSC) market are Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Takara Bio Inc., Astellas Pharma Inc., Fate Therapeutics, ViaCyte, StemCells, Japan Tissue Engineering Co. Ltd., Fate Therapeutics and Japan Tissue Engineering Co . The potential risk of tumour is one of the major restraints on the growth of the Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy. According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market. Companies in the Induced Pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a strategic collaboration to develop iPSC-derived allogenic cell therapies for the treatment of acute myeloid leukemia and multiple myeloma. Furthermore, in May 2022, Evotec and Sernova announced strategic partnership to develop iPSC-based beta cell replacement therapy for treatment for type 1 and type 2 diabetes. National Institute of Health (NIH), a part of Department of Health and Human Services, regulates the market for Induced Pluripotent stem cells (iPSC) in the US. If a company is using, making or planning to acquire iPSCs, they are required to provide some information. For instance, a complete and signed copy of the IPSC checklist must be submitted. Any acquisitions in the IPSC’s must obtain approval from the Institutional review board (IRB), the signed approval documents must be attached to the checklist. If the IPSC lines are purchased from an outside or commercial source these agreement documents must also be attested by the IRB and attached. The IPSC’s must be generated by the Intramural Research Program (IRP) under a signed contract before they can be used for any further experimentation. In August 2021, catalant, a Us-based pharmaceutical company, acquired RheinCell Therapeutics GmbHfor an undisclosed amount. The acquisition will help Catalent to grow in the cell and gene therapy vertical and develop therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH is a Germany-based developer of human induced pluripotent stem cells (iPSCs) for next generation cell therapies. North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2022. Western Europe was the second largest region in the global induced pluripotent stem cell (iPSC) market share. The regions covered in the global induced pluripotent stem cell (iPSC) market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the induced pluripotent stem cell (iPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports from The Business Research Company that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell based assays are experimental tools that are designed to study reactions taking place inside the cells. These assays are used to study a mechanism or process of cellular function. The main product and services for cell based assays are consumables, instruments, services, and software. Consumables are products that are used up or depleted during their use. The various instruments used are microplates, microplate readers, high throughput screening systems, and liquid handling systems. Different consumables include reagents and media, cells and cell lines, probes, and labels. The several technology types of cell based assays are automated handling, flow cytometry, label-free detection, high-throughput screening, and others, and they are applied for drug discovery, basic research, ADME studies, predictive toxicology, and other purposes. The different end users include pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CRO) and others. The global cell based assays market is segmented - 1) By Product & Service: Consumables, Instruments, Services, Software 2) By Application: Drug Discovery, Basic Research, Adme Studies, Predictive Toxicology, Other Applications 3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Government Research Institutes, Contract Research Organizations (CRO), Other End Users 4) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Other Technologies 5) By Consumables: Reagents And Media, Cells And Cell Lines, Probes And Labels 6) By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems The global cell based assays market size will grow from $22.58 billion in 2022 to $24.61 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global cell based assays is expected to grow to $36.22 billion in 2027 at a CAGR of 10.1%. Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of investigational new drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the growth of the cell based arrays market. Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, Merck, Perkinelmer, Promega, Lonza, Charles River Laboratories and Cell Signaling Technology. High cost of instruments is the major factor restraining the global cell based assays market. High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation. For example, Biotek developed HCA (high content analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market. Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation. In May 2022, Cell Carta, a Canada-based provider of precision medicine laboratory services, acquired next-generation immune-MRM assays from Precision assays for an undisclosed amount. The acquisition will solidify Cell Carta’s position in the proteomics vertical and help it better serve the customers. Precision Assays is a US-based provider of next-generation targeted proteomics testing solutions. North America was the largest region in the cell based assays market in 2022. Western Europe was the second largest region in the global cell based assays market share. The regions covered in the global cell based assays market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell based assays market consists of sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cell based assays market research report is one of a series of new reports from The Business Research Company that provides cell based assays market statistics, including cell based assays industry global market size, regional shares, competitors with a cell based assays market share, detailed cell based assays market segments, market trends and opportunities, and any further data you may need to thrive in the cell based assays industry. This cell based assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biotechnology services refer to the services that modify living microorganisms to provide biotechnology products on a contract or custom basis to medical, pharmaceutical, and scientific laboratories. They provide breakthrough products and technologies to combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes. The main types of biotechnology services are prevention and disease control, public engagement activities, health education and research, food biotechnology services, donor recruitment, tissue collection, cell processing and isolation, and research and development. Food biotechnology services encompass a diverse variety of technologies used in crops, livestock, forestry, fisheries and aquaculture, and agro-industry. They are used for a variety of purposes, including genetic improvement of plants and animals to increase yields or efficiency, characterization and conservation of genetic resources for food and agriculture, plant and animal disease diagnosis, vaccine development, and fermented food production. The various applications include pharmaceutical, biotechnological, academic, clinical trial, and healthcare sectors and are used by Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), and Contract Research and Manufacturing Services (CRAMS). The global biotechnology services market is segmented - 1) By Service: Prevention and Disease Control, Public Engagement Activities, Health Education and Research, Food Biotechnology Services, Donor Recruitment, Tissue Collection, Cell Processing and Isolation, Research and Development 2) By Industry: Clinical Research Organizations (CROs), Contract Manufacturers Organizations(CMOs), Contract Research and Manufacturing Services (CRAMS) 3) By Area of Application: Pharmaceutical, Biotechnological, Academic, Clinical Trial, Healthcare Sectors The global biotechnology services market size will grow from $146.85 billion in 2022 to $163.71 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the biotechnology services is expected to grow to $241.17 billion in 2027 at a CAGR of 10.2%. The increasing pervasiveness of conditions like hepatitis B, diabetes, and cancer is driving research in biotechnology. Biotechnology uses research tools from biology and chemistry to study the genetic material of bacteria and viruses to check the disease-producing agents. Oncology research is most prominent among biopharma companies. Stem cell treatment using a monoclonal antibody for therapy and genome sequencing is progressing in medical applications. According to the Indian Economic Survey 2021, the Indian biotechnology business is predicted to grow to US$ 150 billion by 2025. Global R&D spending by the world's largest publicly traded biotech companies increased by 13.7 percent each year, from $4.8 billion in 2001 to $55.0 billion in 2020. Therefore, the rising pervasiveness of diseases and huge expenses on R&D are predicted to contribute to the growth of the biotechnology services market. Major players in the biotechnology services market are Novartis, Fisher BioService, Pfizer, Novo Nordisk, BioAlps, Precision for Medicine, Sartorius and Aldevron. The risk related to genetic data is anticipated to limit the growth of the biotechnology services market. The biotechnological approach of transferring specially created genes for modification in characteristics to create genetically modified organisms (GMOs) has always been considered a threat to human and environmental health. According to the report of the World Conservation Union, there are numerous environmental risks likely to occur due to the use of GMOs, which include interbreeding, antibiotic resistance, impact on the ecosystem, creation of new or worse viruses, competition with natural species, unpredictable and unintended effects, and ethical concerns. The World Health Organization (WHO) has also set guidelines for manufacturers of GMO food. The National Bioengineered Food Disclosure Standard has been implemented in the USA since January 2020, making it mandatory to label all foods containing genetically engineered items as "bioengineered". Thus, the risk associated with genetically modified items is negatively impacting the growth of the biotechnology services market. Collaborations and partnerships between industry players are a growing trend in the field of biotech services. In January 2021, Novartis, a Switzerland-based pharmaceutical company collaborated with Alnylam, a US-based biopharmaceutical company for exploration in the application of the latter’s siRNA technology and the development of targeted therapy for the restoration of liver function. As part of the exclusive three-year research collaboration, Alnylam will develop and test potential siRNAs using Novartis' target-specific assays. Novartis will conduct further development and clinical research once a lead candidate has been identified. In October 2021, Amgen, a US-based biopharmaceutical company, acquired all outstanding shares of Teneobio for a deal amount of $2.5 billion. Amgen acquired Teneobio's bispecific and multispecific antibody technologies as part of the acquisition. These solutions complement the company's existing antibody expertise and BiTE platform. This will aid in the discovery and advancement of novel molecules for the treatment of a wide range of illnesses in Amgen's major treatment areas. TeneoBio is a US-based biotechnology business that specialises in the production of human heavy chain antibodies. Asia-Pacific was the largest region in the biotechnology services market in 2022. North America was the second largest region in the global biotechnology services market analysis. The regions covered in the global biotechnology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biotechnology services market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biotechnology services market consists of revenue earned by entities that engage in conducting research and experimental development in biotechnology. Numerous global issues are helped by biotechnology, including infectious diseases, ageing societies, food security, energy security, and climate change, to name a few. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The biotechnology services market research report is one of a series of new reports from The Business Research Company that provides biotechnology services market statistics, including biotechnology services industry global market size, regional shares, competitors with a biotechnology services market share, detailed biotechnology services market segments, market trends and opportunities, and any further data you may need to thrive in the biotechnology services industry. This biotechnology services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI) is a simulation of the human intelligence in machines that are programmed to think and behave like humans. AI helps to complete the job quickly and with relatively few errors. The main technologies in artificial intelligence (AI) in drug discovery are deep learning and machine learning. Deep learning is a machine learning and artificial intelligence (AI) technique that mimics how humans acquire knowledge. Data science, which covers statistics and predictive modelling, incorporates deep learning as a key component. The different drug types include small molecule, large molecules and involves various types of therapies such as c, others. It is implemented in several end-users including pharmaceutical companies, biopharmaceutical companies, academic and research institutes, others. The global artificial intelligence (AI) in drug discovery market is segmented – 1) By Technology: Deep Learning, Machine Learning 2) By Drug Type: Small Molecule, Large Molecules 3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Other Therapeutics 4) By End-Users: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users The global artificial intelligence (ai) in drug discovery market size will grow from $1.04 billion in 2022 to $1.38 billion in 2023 at a compound annual growth rate (CAGR) of 31.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global artificial intelligence (ai) in drug discovery market size is expected to grow to $3.74 billion in 2027 at a CAGR of 28.4%. The rise in demand for a reduction in the overall time taken for the drug discovery process is a key driver propelling the growth of the artificial intelligence (AI) in drug discovery market. Traditionally, it takes three to five years for animal models to identify and optimize molecules before they are evaluated in humans whereas start-ups based on AI have been identifying and designing new drugs in a matter of few days or months. For instance, in 2020, the British start-up Exscientia and Japan's Sumitomo Dainippon Pharma have used artificial intelligence to produce an obsessive-compulsive disorder (OCD) medication, decreasing the development time from four years to less than one year. The reduction in overall time taken for the drug discovery process drives the artificial intelligence (AI) in drug discovery market’s growth. Major players in the artificial intelligence (AI) in drug discovery market are IBM Corporation, Microsoft, Atomwise Inc., Deep Genomics, Cloud Pharmaceuticals, Insilico Medicine, Benevolent AI, Exscientia, Cyclica and BIOAGE. The shortage of skilled professionals is expected to hamper the AI in drug discovery market. The employees have to re-train or learn new skill sets to work efficiently on the complex AI machines to get the desired results for the drug. The shortage of skills acts as a major hindrance to drug discovery through AI, discouraging companies to adopt AI-based machines for drug discovery. in 2020, according to a study by National Skills Coalition, one-third of America's workers lacked digital skills. This figure accounted for 18% of workers with only a few skills and 13% with no digital abilities. Major companies operating in the AI drug delivery market are adopting strategic collaborations to research and discover drugs using AI and are gaining significant popularity in the artificial intelligence in drug discovery market. For instance, in August 2022, Atomwise, a US-based artificial intelligence systems company, partnered with Sanofi. The partnership aimed at computationally identifying and investigating up to five pharmacological targets using the Atomwise AI-powered AtomNet technology. To find, create, and advance lead compounds for up to five Sanofi-exclusive targets, Atomwise received a $20 million upfront payment from Sanofi. Sanofi is a French pharmaceutical and healthcare company. In July 2020, Curi Bio, a leading developer of human iPSC-based platforms for drug discovery, acquired Dana Solutions for an undisclosed amount. This acquisition will give Curi Bio access to Dana's AI/ML platforms for modelling cell and tissue phenotype, automated platform for contractility analysis of beating cardiomyocyte and platform for predictive safety pharmacology. Dana Solutions is a leading AI solutions provider for the life sciences industry. North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2022. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the global artificial intelligence (AI) in drug discovery market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the artificial intelligence (AI) in drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The artificial intelligence (AI) in drug discovery market includes revenues earned by entities by offering AI for drug discovery. Artificial Intelligence (AI) for drug discovery is a technology that uses a simulation of the human intelligence process by machines to tackle complex problems in the drug discovery process. It helps to find new molecules to identify drug targets and develop personalized medicines in the pharmaceutical industry. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The artificial intelligence (AI) in drug discovery market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in drug discovery market statistics, including artificial intelligence (AI) in drug discovery industry global market size, regional shares, competitors with a artificial intelligence (AI) in drug discovery market share, detailed artificial intelligence (AI) in drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in drug discovery industry. This artificial intelligence (AI) in drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell culture consumables and equipment are designed to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. The main products in cell culture consumables and equipment are consumables and instruments. The cell culture instruments involve the various instruments that are required for cell culture in the cell culture laboratory. The various instruments used in cell culture are cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, and centrifuge and consumables are media, sera, and reagents. The applications involved are vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, and others that are used by end-users such as industrial, biotechnology, agriculture, and others. The global is segmented - 1) By Product: Consumables, Instruments 2) By End User: Industrial, Biotechnology, Agriculture, Other End Users 3) By Application: Vaccination, Toxicity testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem cell technology, Regenerative Medicine, Other End Users 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges The global cell culture consumables and equipment market grew from $10.99 billion in 2022 to $12.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the cell culture consumables and equipment is expected to grow from $17.98 billion in 2027 at a CAGR of 10.4%. An increase in the prevalence of chronic diseases is driving the growth of the cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity, and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain types of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth of this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Major players in the cell culture consumables and equipment market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, and PromoCell GmbH. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has several negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycoplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques poses a threat to the growth of the cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three-dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with a higher degree of structural complexity and maintain the steady-state for more time as compared to 2D cell cultures. In August 2021, Amerigo Scientific, a US-based manufacturer of biomedical and life sciences products, launched #D cell cultures for research purposes. FDA regulates cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment, the FDA states that if the equipment is not labelled or mentioned as sterile, it would be removed from the good manufacturing practises of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality, along with the documentation of the receipts. Therefore, these regulatory standards improve the safety and efficacy of instruments and consumables used during cell culture processes. In July 2021, Sartorius, a Germany-based laboratory instrument manufacturer, acquired Xell AG for an undisclosed amount. The acquisition would expand Sartorius’ current media offering and other cell culture products. Xell AG is a Germany-based cell culture specialist. North America was the largest region in the cell culture consumables and equipment market in 2022. Western Europe was the second largest region in the global cell culture consumables and equipment market share. The regions covered in the global cell culture consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture consumables and equipment market consists of sales of flasks, tubes, dishes or cryovials, serological pipettes or centrifugation tubes, bottles, cell scrapers, strainers, coverslips, and inserts. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The cell culture consumables and equipment market research report is one of a series of new reports from The Business Research Company that provides cell culture consumables and equipment market statistics, including cell culture consumables and equipment industry global market size, regional shares, competitors with a cell culture consumables and equipment market share, detailed cell culture consumables and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture consumables and equipment industry. This cell culture consumables and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.